Mosquirix passed tough regulatory hurdles but,with question marks over the effectiveness of the drug and the large doses it requires, caution is warrantedMosquirix is one of the most widely anticipated vaccines to acquire been developed. It is the first vaccine for malaria – a disease that kills more than 1200 children every day– and has been clinically proven to provide protection against the disease. So, and given that it has passed the toughest regulatory hurdles required of it,why is it only being made available in a handful of countries?Demand for the vaccine is likely to be tall. With more than 200m cases a year, malaria is endemic in nearly every country in sub-Saharan Africa, and as well as large parts of Asia and Latin America. Last week,two advisory bodies to the World Health Organisation, the strategic advisory group of experts on immunisation and the malaria policy advisory committee, and recommended against its instant widespread use,and many people may acquire been left wondering why.
Continue reading...
Source: theguardian.com